Esperion Therapeutics (ESPR) Free Cash Flow Growth (3y) (2015 - 2026)
Esperion Therapeutics (ESPR) Free Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn | 39.19% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 19.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.92% |
| Dec 31, 2025 | 45.19% |
| Sep 30, 2025 | 53.57% |
| Jun 30, 2025 | 14.65% |
| Mar 31, 2025 | 16.59% |
| Dec 31, 2024 | 15.39% |
| Sep 30, 2024 | 19.95% |
| Jun 30, 2024 | 46.57% |
| Mar 31, 2024 | 37.57% |
| Dec 31, 2023 | 18.61% |
| Sep 30, 2023 | 39.34% |
| Jun 30, 2023 | -29.63% |
| Mar 31, 2023 | 7.88% |
| Dec 31, 2022 | 5.36% |
| Sep 30, 2022 | 9.44% |
| Jun 30, 2022 | 2.33% |
| Mar 31, 2022 | -34.37% |
| Dec 31, 2021 | -26.00% |
| Sep 30, 2021 | -22.61% |
| Jun 30, 2021 | -6.89% |